Fig. 1: EZH2 inhibition significantly reduced tumour burden in mice bearing 5T33MM multiple myeloma.
From: A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
a Western blot against H3K27me3 and total histone H3 (H3) of bone marrow plasma cells derived from 5T33MM mice treated with 150 or 300 mg/kg of UNC1999, or with vehicle. Total histone H4 (H4) was used as a loading control. Corresponding uncropped western blots can be found in Supplementary Fig. 9a–b. b Signal quantification of the western blot against H3K27me3 shown in (a). c Signal quantification of the western blot against H3 shown in (a). The optical density in (b–c) was normalized against H4. n(Vehicle) = 4, n(150 mg/kg) = 5 and n(300 mg/kg) = 4. Statistical analysis in (b–c) was performed with one-way ANOVA. Values: mean with SEM. d–f 5T33MM mice were treated with 200 mg/kg of UNC1999 or with vehicle. Tumour load was determined by d bone marrow plasmacytosis, e M-spike levels and f spleen weight. n(Vehicle) = 8, n(UNC1999) = 6. Statistical analysis in (d–f) was performed with one-sided t-test. Values: mean with SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
